Transgene Biotek

Transgene Biotek Current Liabilities

The Current Liabilities of Transgene Biotek (526139.BO) as of Oct 30, 2026 is 14.75 M INR. In the previous year, Current Liabilities was 16.65 M INR — a change of -11.42% (lower).

Current Liabilities

14.75 MINR

YoY

-11.42%

Last updated:

Current Liabilities of Transgene Biotek is 2026 14.75 M INR. Current Liabilities of Transgene Biotek was 2025 16.65 M INR. It decreases by -11.42% lower compared to the previous year.

The Transgene Biotek Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
75.06 M INR
Jan 1, 2020
70.59 M INR
Jan 1, 2021
2.60 M INR
Jan 1, 2022
2.40 M INR
Jan 1, 2023
3.25 M INR
Jan 1, 2024
2.41 M INR
Jan 1, 2025
16.65 M INR
Jan 1, 2026
14.75 M INR
The Transgene Biotek Current Liabilities history
YEARCurrent LiabilitiesYoY
14.75 MINR-11.42%
16.65 MINR+591.65%
2.41 MINR-25.91%
3.25 MINR+35.25%
2.40 MINR-7.40%
2.60 MINR-96.32%
70.59 MINR-5.95%
75.06 MINR-4.07%
78.25 MINR+755.56%
9.15 MINR-91.92%
113.26 MINR-55.13%
252.39 MINR-1.25%
255.60 MINR-27.10%
350.60 MINR-27.40%
482.90 MINR+637.25%
65.50 MINR+364.54%
14.10 MINR-0.70%
14.20 MINR+39.22%
10.20 MINR+14.61%
8.90 MINR+41.27%
6.30 MINR-26.74%
8.60 MINR+100.00%
4.30 MINR-55.21%
9.60 MINR+95.92%
4.90 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Transgene Biotek Stock analysis

What does Transgene Biotek do? Transgene Biotek Ltd. generates revenue through the sale of diagnostic kits and its portfolio of products, including oncology, auto-immunity, drug delivery, and biogenerics solutions. The company offers TrabiAAV, a platform for delivering miRNAs, ShRNAs, and immunogens in gene therapy, and TrabiORAL, which enables oral delivery of proteins and peptides for treating human diseases. Its TBL-1203 product strengthens cell-mediated immunity to eliminate HIV without retroviral therapy, while Tacrolimus suppresses the immune system to prevent organ transplant rejection. These products are targeted at healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. The firm’s R&D focus on vaccines, oncology, and new drug delivery technologies supports its product development pipeline. TrabiAAV and TrabiORAL are positioned as innovative delivery platforms, while TBL-1203 and Tacrolimus address specific medical needs in HIV treatment and transplant medicine. The company’s diagnostic kits cater to clinical laboratories and hospitals requiring reliable testing solutions for oncology and autoimmune conditions. Transgene Biotek Ltd. serves healthcare professionals, pharmaceutical firms, and research organizations through its specialized products. Its oncology and auto-immunity kits are used in diagnostic settings, while its therapeutic platforms like TrabiAAV and TrabiORAL support drug development for complex diseases. The company’s focus on biogenerics and novel delivery systems aligns with market demands for cost-effective and targeted therapies. Transgene Biotek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene Biotek stock

Current Liabilities of Transgene Biotek is 14.75 M INR in 2026.

Current Liabilities of Transgene Biotek changed from 16.65 M INR to 14.75 M INR, representing a -11.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Transgene Biotek since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Transgene Biotek historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Transgene Biotek

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Transgene Biotek